A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

As the UK market grapples with the repercussions of faltering trade data from China, the FTSE 100 and FTSE 250 indices have experienced declines, reflecting broader global economic concerns. In such a ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...